comparemela.com

Latest Breaking News On - Consortium for enhanced sepsis outcomes - Page 2 : comparemela.com

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023

EQS-News: Heidelberg Pharma AG / Key word(s): 9 Month figuresHeidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023 12.10.2023 / 07:09 CET/CESTThe issuer is solely responsible for the content of this announcement.Heidelberg Pharma AG: Interim Management Statement on the First Nine Months.

RedHill s RHB-107 Included in U S Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RHB-107 (upamostat)3 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funde

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.